CellaVision AB (CLVSF)
14.00
0.00 (0.00%)
USD |
OTCM |
Oct 16, 16:00
CellaVision Research and Development Expense (Annual) : 8.875M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 8.875M |
| December 31, 2024 | 7.335M |
| December 31, 2023 | 6.954M |
| December 31, 2022 | 7.192M |
| December 31, 2021 | 6.633M |
| December 31, 2020 | 4.988M |
| December 31, 2019 | 5.473M |
| December 31, 2018 | 5.044M |
| December 31, 2017 | 3.072M |
| December 31, 2016 | 3.368M |
| December 31, 2015 | 3.162M |
| Date | Value |
|---|---|
| December 31, 2014 | 3.225M |
| December 31, 2013 | 3.090M |
| December 31, 2012 | 3.085M |
| December 31, 2011 | 3.235M |
| December 31, 2010 | 2.348M |
| December 31, 2009 | 1.536M |
| December 31, 2008 | 3.070M |
| December 31, 2007 | 2.551M |
| December 31, 2006 | 1.956M |
| December 31, 2005 | 1.470M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ALR Technologies SG Ltd. | -- |
| Carasent AB | -- |
| PHC Holdings Corp. | 72.43M |
| SyntheticMR AB | 0.9463M |
| HealthStream, Inc. | 50.98M |